RxSight, Inc. (RXST) Income Statement
RXST 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRXST revenue and net income
Where RXST's revenue goes
2025Each bar shows an amount and its share of revenue. RXST kept −29.0% of revenue as net income.
RXST profit margins
RXST growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −3.9% | +40.0% | +55.7% | — |
| Gross profit | +4.1% | +69.0% | +127.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RXST quarterly EPS vs estimates
RxSight beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.42).
RXST income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M | $14.7M | $2.2M |
| Cost of revenue | $31.5M | $41.0M | $35.3M | $27.7M | $18.1M | $13.0M | $4.1M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M | $1.7M | −$1.8M |
| Research & development | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M | $21.9M | $29.6M |
| Sales, general & admin | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M | $15.2M | $15.2M |
| Total operating expenses | $151.2M | $135.8M | $103.8M | $84.6M | $57.3M | $37.1M | $44.3M |
| Operating income | −$48.2M | −$36.9M | −$50.1M | −$63.3M | −$52.8M | −$35.4M | −$46.1M |
| Interest income | $9.3M | $9.5M | $6.6M | $1.5M | $54,000 | $543,000 | $2.3M |
| Interest expense | $40,000 | $21,000 | $3.3M | $4.9M | $3.7M | $510,000 | $26,000 |
| Income before taxes | −$38.9M | −$27.4M | −$48.6M | −$66.7M | −$48.7M | $27.6M | $126.2M |
| Income taxes | $66,000 | $50,000 | $20,000 | $9,000 | $8,000 | $57,000 | $24,000 |
| Net income | −$38.9M | −$27.5M | −$48.6M | −$66.8M | −$48.7M | $27.6M | $126.2M |
| EBITDA | −$35.6M | −$23.8M | −$41.0M | −$57.8M | −$41.0M | $32.2M | $130.2M |
| EPS (diluted) | −$0.59 | −$0.41 | −$1.04 | −$2.42 | −$2.13 | −$1.70 | — |
| Gross margin | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% | 11.6% | −81.2% |
| Operating margin | −35.8% | −26.3% | −56.2% | −129.2% | −233.6% | −241.2% | −2,055.8% |
| Net margin | −29.0% | −19.6% | −54.6% | −136.2% | −215.5% | 187.9% | 5,632.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.7M | $30.9M | $32.6M | $30.3M | $33.6M | $37.9M | $40.2M | $45.4M | $34.9M | $29.5M | $28.6M | $30.7M |
| Cost of revenue | $7.9M | $7.4M | $7.3M | $6.1M | $8.4M | $9.6M | $11.4M | $20.2M | $10.6M | $8.8M | $10.9M | $16.9M |
| Gross profit | $25.9M | $23.5M | $25.3M | $24.2M | $25.2M | $28.3M | $28.8M | $25.2M | $24.2M | $20.7M | $17.7M | $13.7M |
| Research & development | $9.2M | $9.5M | $8.9M | $9.1M | $10.2M | $10.4M | $9.2M | $8.8M | $8.3M | $8.0M | $7.3M | $7.1M |
| Sales, general & admin | $30.4M | $31.9M | $27.7M | $27.3M | $29.0M | $28.6M | $28.2M | $25.6M | $24.3M | $23.3M | $21.2M | $19.1M |
| Total operating expenses | $39.7M | $41.3M | $36.6M | $36.4M | $39.2M | $39.0M | $37.4M | $34.4M | $32.6M | $31.4M | $28.5M | $26.2M |
| Operating income | −$13.8M | −$17.8M | −$11.3M | −$12.2M | −$14.0M | −$10.7M | −$8.6M | −$9.2M | −$8.3M | −$10.7M | −$10.9M | −$12.5M |
| Interest income | $1.8M | $2.0M | $2.2M | $2.4M | $2.3M | $2.5M | $2.7M | $2.9M | $2.3M | $1.6M | $1.7M | $1.7M |
| Interest expense | $3,000 | $3,000 | $5,000 | $4,000 | $5,000 | $6,000 | $5,000 | $5,000 | $6,000 | $6,000 | $4,000 | $230,000 |
| Income before taxes | −$12.0M | −$15.9M | −$9.1M | −$9.8M | −$11.8M | −$8.2M | −$5.9M | −$6.3M | −$6.1M | −$9.1M | −$9.2M | −$12.4M |
| Income taxes | $88,000 | $6,000 | $6,000 | $10,000 | $32,000 | $18,000 | $12,000 | $13,000 | $16,000 | $9,000 | −$18,000 | $12,000 |
| Net income | −$12.1M | −$15.9M | −$9.2M | −$9.8M | −$11.8M | −$8.2M | −$5.9M | −$6.3M | −$6.1M | −$9.1M | −$9.2M | −$12.4M |
| EBITDA | −$11.0M | −$15.0M | −$8.3M | −$8.9M | −$11.0M | −$7.4M | −$5.4M | −$5.2M | −$5.2M | −$7.9M | −$8.1M | −$11.0M |
| EPS (diluted) | −$0.29 | −$0.19 | −$0.03 | −$0.24 | −$0.29 | −$0.03 | $0.03 | −$0.16 | −$0.16 | −$0.12 | −$0.26 | −$0.19 |
| Gross margin | 76.7% | 76.1% | 77.5% | 79.9% | 74.9% | 74.8% | 71.6% | 55.5% | 69.5% | 70.1% | 61.8% | 44.8% |
| Operating margin | −40.8% | −57.7% | −34.8% | −40.1% | −41.6% | −28.2% | −21.5% | −20.3% | −23.9% | −36.2% | −38.0% | −40.8% |
| Net margin | −35.9% | −51.4% | −28.1% | −32.4% | −35.0% | −21.6% | −14.8% | −14.0% | −17.4% | −30.8% | −32.1% | −40.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RXST's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RXST financial results
In fiscal year 2025 (ended December 31, 2025), RxSight reported revenue of $134.5 million, down 3.9% from the year before. It had a net loss of $38.9 million, a net profit margin of −29.0%. Diluted earnings per share came to −$0.59. Over five years revenue grew at an average rate of 55.7% a year.
See the RXST stock overview for the latest quote and news, or the RXST chart for price history and technical indicators.
RXST income statement FAQ
What is RxSight's annual revenue?
RxSight reported total revenue of $134.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 3.9% from $139.9 million the previous year.
Is RxSight profitable?
No. RxSight reported a net loss of $38.9 million in fiscal 2025, a net profit margin of −29.0%; its operating margin was −35.8%.
What is RxSight's gross margin?
RxSight's gross margin was 76.6% in fiscal 2025: for every $100 of revenue, RxSight kept $77 after the direct cost of its products and services.
How much does RxSight spend on research and development?
RxSight spent $38.5 million on research and development in fiscal 2025, 28.7% of revenue.
How fast is RxSight growing?
Revenue grew 55.7% a year on average over the last five fiscal years, from $14.7 million to $134.5 million.
What are RxSight's earnings per share?
RxSight earned $-0.59 per diluted share in fiscal 2025, compared with $-0.41 a year earlier.
When will RxSight report its next earnings?
RxSight is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does RxSight's fiscal year end?
RxSight's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.